Clinical Study

Chronic Gastritis in Dermatitis Herpetiformis: A Controlled Study

Anna Alakoski, 1 Teeta T. Salmi, 1, 2 Kaisa Hervonen, 1, 2 Hannu Kautiainen, 3 Maarit Salo, 4 Katri Kaukinen, 2, 5 Timo Reunala, 1, 2 and Pekka Collin 2, 5

1 Department of Dermatology, Tampere University Hospital, 33521 Tampere, Finland
2 School of Medicine, University of Tampere, 33014 Tampere, Finland
3 Unit of Family Practice, Central Finland Central Hospital, and Unit of Primary Health Care, Kuopio University Hospital, 70211 Kuopio, Finland
4 Valkeakoski Regional Hospital, Department of Medicine, 37600 Valkeakoski, Finland
5 Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, P.O. Box 2000, 33521 Tampere, Finland

Correspondence should be addressed to Pekka Collin, pekka.collin@uta.fi

Received 9 January 2012; Accepted 27 February 2012

Academic Editor: Alessio Fasano

Copyright © 2012 Anna Alakoski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Objective. Previous small studies suggest that chronic atrophic gastritis is common in dermatitis herpetiformis (DH). We here examined the frequency and topography of chronic gastritis in 93 untreated DH subjects and in 186 controls with dyspepsia.

Methods. Specimens were drawn from the gastric corpus and antrum and examined for atrophy, intestinal metaplasia, and Helicobacter pylori. Duodenal biopsies were taken.

Results. Atrophic corpus gastritis was more frequent in DH than in controls (16.0% and 2.7%, resp., \( P < 0.001 \)); atrophy in the antrum was rare in both groups (3.2% and 1.1%, \( P = 0.34 \)). Intestinal metaplasia was present in 13 (14.0%) DH and 12 (6.5%) control patients (\( P = 0.038 \)) and \( H. \) pylori in 17 (18.3%) and 17 (9.3%) (\( P = 0.028 \)), respectively. Small-bowel villous atrophy was seen in 76% of the DH patients, equally in patients with and without chronic gastritis. One DH patient with atrophic gastritis developed gastric cancer.

Conclusion. In DH, chronic atrophic gastritis was common in the corpus, but not in the antrum. \( H. \) pylori will partly explain this, but corpus atrophy is suggestive of an autoimmune etiology. Atrophic gastritis may increase the risk of gastric cancer. We advocate performing upper endoscopy with sufficient histologic samples in DH.

1. Introduction

The majority of patients with dermatitis herpetiformis (DH) evince small-bowel mucosal damage or inflammation similar to that in classic or early-stage celiac disease [1, 2]. Patients rarely suffer from abdominal symptoms, and irrespective of small-bowel mucosal morphology, the rash in DH responds to a gluten-free diet, the treatment of choice for the condition [3, 4]. Coeliac disease and DH share a similar genetic background and occur frequently in the same families; even identical twins may have different phenotypes [5, 6]. Tissue-type transglutaminase is the major autoantigen in coeliac disease, but an immune response to epidermal transglutaminase is probably essential for the development of DH, although this is not fully proven [7, 8]. Altogether, DH is indisputably an extraintestinal manifestation of coeliac disease.

Again similarly to coeliac disease, autoimmune conditions occur together with DH [9]. Earlier studies indicate that chronic atrophic gastritis (CAG) is common in DH and may be of autoimmune origin, but the data are based on a limited number of patients only [10–12]. Helicobacter pylori infection is the main agent causing chronic gastritis [13, 14], but autoimmune gastritis may also occur. \( H. \) pylori gastritis is often patchy and affects the antral mucosa, whereas autoimmune gastritis occurs typically in the corpus of the stomach.

The Sydney System is a systematic approach to determine the topography, morphology, etiology, and severity of gastritis [15]. It has not previously been applied in DH. Small-intestinal biopsy helps to estimate the severity of villous atrophy but is not necessary for the ultimate diagnosis of DH. Provided that CAG is common in patients with DH, this
would constitute a further indication for endoscopy. In the present study we examined the occurrence of CAG and H. pylori, as classified by the Sydney System, in a large series of DH patients sampled over the past 20 years. The histologic data were compared to those from patients of similar sex and age who were suffering from dyspepsia.

2. Material and Methods

The study was carried out over the period 1990–2009 at the Department of Dermatology, Tampere University Hospital. The cohort comprised 93 patients with DH, from whom biopsy samples had been taken from duodenum and from stomach for the classification of gastritis according to the Sydney System. The diagnosis of DH was based on the typical clinical picture and direct immunofluorescence showing granular IgA deposits in the papillary dermis in the unin- volved skin [16]. Patients’ medical records were examined. Duodenal biopsy specimens were graded as subtotal villous atrophy, partial villous atrophy, and normal mucosa. Gastric mucosal atrophy was graded from 0 to 3, grade 0 indicating normal morphology and 3 the most severe involvement, in line with the Sydney System [15]. H. pylori was not graded, since a positive finding anywhere in the stomach was considered diagnostic for the infection. The patients with DH were regularly followed up in the special outpatient clinic for 1–2 years [17]. A questionnaire was sent to all DH patients who were alive in 2011, and it included questions on adherence to the gluten-free diet, the use of dapsone, and the occurrence of associated diseases and malignancies.

The control group comprised patients suffering from dyspepsia and undergoing upper gastrointestinal endoscopy at the Regional Hospital of our catchment area in 2009–2011. Two control patients of similar sex and age (±5 years) and no small-bowel mucosal villous atrophy were chosen for each DH case, the final series thus consisting of 186 control patients.

The statistical differences between DH and control patients with and without CAG were calculated by chi-square test or Fisher’s exact test when appropriate. Odds ratios were given with 95% confidence intervals.

The study was based on the case records, and permission to read these was obtained. A statement of the Ethical Committee was not considered obligatory.

### 3. Results

Atrophy of the corpus and intestinal metaplasia were significantly more common in DH than in the control subjects (Table 1). By contrast, there was no significant difference between the groups in the occurrence of antral atrophy, which was altogether a relatively uncommon finding. The mean score for atrophy in the corpus was 1.6 in DH patients and 2.3 in control subjects.

Seven (44%) DH patients with CAG had associated intestinal metaplasia in the body of the stomach and additional two patients in the antrum (Table 2). H. pylori infection was significantly more frequent in DH than in controls (18% and 9%, resp., Table 1). One patient (no. 3, Table 2) with pangastritis and intestinal metaplasia in the initial biopsy developed gastric cancer one year later. Forty-four percent of DH patients with CAG showed H. pylori in the gastric mucosa, compared to 14% without CAG (Table 3).

Table 3 shows the 16 DH patients with CAG to be older (mean 63 years) than the 78 without (mean 44 years). Small-intestinal villous atrophy was found in 76.6% of patients with DH and was equally common in patients with and without CAG. Thirty percent of patients with DH reported abdominal complaints; again, there was no significant difference between patients with or without CAG (Table 3).

All 16 DH patients with CAG started a gluten-free diet after the diagnosis of DH, nine in addition using daily 25 mg to 50 mg of dapsone to control the rash. All maintained a strict diet and no longer needed dapsone at the end of the followup.

Associated autoimmune diseases were found in three DH patients with CAG; one had hypothyroidism, one pernicious anaemia and Graves’ disease, and one vitiligo (Table 2). One DH patient with CAG developed prostate cancer, and two patients had had breast cancer before the diagnosis of DH.

### 4. Discussion

The frequency of CAG in the corpus was significantly more common in the DH patients than in the control subjects suffering from dyspepsia. No such a difference was seen in the antrum of the stomach. Previously, Primignani et al. [12] conducted a study in 57 Italian patients with DH and found a prevalence of CAG of 30%, compared to 15% in non-DH

---

**Table 1: Gastric findings in the 93 patients with dermatitis herpetiformis (female 40, median age 48 years; range 7–76) and 186 control patients with dyspepsia (female 80, median age 56 years; range 18–86).**

|                     | Dermatitis herpetiformis | Control patients | Odds ratio | P-value |
|---------------------|--------------------------|------------------|------------|---------|
|                     | n = 93                   | n = 186          |            |         |
| Corpus atrophy      | 15 (16.0%)               | 5 (2.7%)         | 6.96 (CI 2.29–25.16) | <0.001  |
| Antrum atrophy      | 3 (3.2%)                 | 2 (1.1%)         | 3.07 (CI 0.34–37.16) | 0.34    |
| Intestinal metaplasia¹ | 13 (14.0%)             | 12 (6.5%)         | 2.36 (CI 1.05–5.30) | 0.038   |
| Helicobacter pylori¹ | 17 (18.3%)               | 17 (9.1%)        | 2.22 (CI 1.09–4.54) | 0.028   |

¹in corpus or antrum.
| Patient no. | Sex/age (years) | Year of DH diagnosis | Corpus atrophy/metaplasia | Gastric findings | Helicobacter pylori | Duodenal histology at diagnosis/on GFD | Associated autoimmune diseases and malignancies |
|------------|-----------------|----------------------|---------------------------|------------------|--------------------|----------------------------------------|-----------------------------------------------|
| 1          | F/53            | 1996                 | 1/1                       | 0/0              | –                  | PVA                                    | Breast cancer 1992                           |
| 2          | F/69            | 1999                 | 1/0                       | 0/0              | –                  | PVA                                    | —                                             |
| 3          | M/68            | 2000                 | 1/2                       | 2/2              | –                  | PVA/N                                  | Gastric cancer 2001                          |
| 4          | M/64            | 2001                 | 3/2                       | 0/0              | –                  | PVA/N                                  | Hypothyreosis >10 yrs before DH diagnosis    |
| 5          | M/61            | 2001                 | 1/0                       | 0/1              | –                  | N/N                                    | Prostate cancer 2010                         |
| 6          | F/58            | 2001                 | 1/0                       | 0/0              | +                  | PVA/N                                  | —                                             |
| 7          | F/62            | 2001                 | 2/0                       | 0/0              | –                  | PVA                                    | —                                             |
| 8          | M/57            | 2001                 | 1/0                       | 0/0              | +                  | PVA                                    | Breast cancer 1992                          |
| 9          | M/48            | 2002                 | 1/0                       | 0/0              | +                  | N                                      | —                                             |
| 10         | M/71            | 2003                 | 2/1                       | 0/0              | –                  | N                                      | Vitiligo 2003                                |
| 11         | F/56            | 2003                 | 3/1                       | 0/0              | –                  | PVA/N                                  | Pernicious anemia 2004                       |
| 12         | M/71            | 2004                 | 2/1                       | 0/2              | +                  | N                                      | Graves’ disease 2005                         |
| 13         | M/76            | 2006                 | 3/2                       | 0/1              | –                  | N                                      | —                                             |
| 14         | F/74            | 2007                 | 1/0                       | 1/0              | +                  | PVA                                    | —                                             |
| 15         | F/63            | 2007                 | 1/0                       | 0/0              | +                  | SVA                                    | —                                             |
| 16         | M/69            | 2008                 | 0/0                       | 2/2              | +                  | SVA                                    | —                                             |

SVA: subtotal villous atrophy, PVA: partial villous atrophy, N: normal mucosa at diagnosis and on a gluten-free diet (GFD).

1Score 0–3 according to the Sydney System.
control subjects with dyspepsia ($P < 0.05$). Patients with DH do not usually suffer from dyspepsia, and therefore the control group was not analogous to the study group. Storskrubb et al. [18] carried out esophago-gastroduodenoscopy at random for 1000 Swedish adults. The overall frequency of corpus atrophy was 5% and antrum atrophy 2%. Our data thus indicate that atrophic corpus gastritis is more common in patients with DH than in the population in general.

*Helicobacter pylori* infection is common in CAG [13, 14, 19]. In line with this, the present DH patients with CAG had *H. pylori* significantly more often than those without CAG. This may be partly explained by the age difference; *H. pylori* is more common in older people, and our patients with GAG were older than those without (Table 3). However, the presence of *H. pylori* in all DH patients (18.3%) was significantly higher than among dyspeptic control subjects with a similar age distribution (9.1%, Table 1). By comparison, Crabtree et al. [20] examined 58 DH patients in Britain and by serological methods found *H. pylori* IgG antibodies in 63% of patients, this frequency being however only slightly higher than in other dermatological patients.

There are some limitations to the present study. It was based on the case records, and it was not possible to re-read the biopsy samples. Nevertheless, we considered that the activity of gastritis, as defined by the Sydney System, [15] would have been unreliable to analyze here. Circulating parietal cell and intrinsic factor antibodies could not be determined. Our DH patients were recruited during the years 1990–2009, whereas the controls were enrolled later, in 2009–2011. This may have affected the results in that during the last decades, the prevalence of *H. pylori* has decreased in Finland here did not present with any specific gastrointestinal symptoms. One DH patient with CAG developed gastric cancer. In untreated DH we recommend upper gastrointestinal endoscopy, upon which biopsy specimens should be taken not only from the duodenum but also from the gastric corpus and antrum.

### 5. Conclusion

The present controlled study showed that patients with DH have at the time of the diagnosis a significantly increased frequency of CAG in the corpus but not in the antrum. In addition to *H. pylori* infection, autoimmune mechanisms may be implicated in the development of gastritis. The DH patients here did not present with any specific gastrointestinal symptoms. One DH patient with CAG developed gastric cancer. In untreated DH we recommend upper gastrointestinal endoscopy, upon which biopsy specimens should be taken not only from the duodenum but also from the gastric corpus and antrum.

### Acknowledgment

This study was financially supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9L006, 9F063, 9M034, and 9N062).
References

[1] J. Marks, S. Shuster, and A. J. Watson, “Small-bowel changes in dermatitis herpetiformis,” *The Lancet*, vol. 2, no. 7476, pp. 1280–1282, 1966.

[2] D. J. Gawrodneg, J. N. Blackwell, H. M. Gilmour, E. A. Rifkind, R. C. Heading, and R. S. Barnetson, “Dermatitis herpetiformis: diagnosis, diet and demography,” *Gut*, vol. 25, no. 2, pp. 151–157, 1984.

[3] T. Reunala, P. P. Seash, D. J. Richards, and A. V. Hoffbrand, “Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal,” *The Lancet*, vol. 1, no. 7798, pp. 288–291, 1973.

[4] T. Reunala, K. Blomqvist, S. Tarpila, H. Halme, and K. Kangas, “Gluten-free diet in dermatitis herpetiformis. I. Clinical response of skin lesions in 81 patients,” *British Journal of Dermatology*, vol. 97, no. 5, pp. 473–480, 1977.

[5] T. Reunala, “Incidence of familial dermatitis herpetiformis,” *British Journal of Dermatology*, vol. 134, no. 3, pp. 394–398, 1996.

[6] K. Hervonen, K. Karell, P. Holopainen, P. Collin, J. Partanen, and T. Reunala, “Concordance of dermatitis herpetiformis and celiac disease in monozygous twins,” *Journal of Investigative Dermatology*, vol. 155, no. 6, pp. 990–993, 2000.

[7] W. Dieterich, T. Ehnis, M. Bauer et al., “Identification of tissue transglutaminase as the autoantigen of celiac disease,” *Nature Medicine*, vol. 3, no. 7, pp. 797–801, 1997.

[8] M. Särö, S. Kärpätä, B. Merkl, M. Paulsson, and N. Smyth, “Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis,” *Journal of Experimental Medicine*, vol. 195, no. 6, pp. 747–757, 2002.

[9] T. Reunala and P. Collin, “Diseases associated with dermatitis herpetiformis,” *British Journal of Dermatology*, vol. 136, no. 3, pp. 315–318, 1997.

[10] D. P. O’Donoghue, M. Lancaster Smith, G. D. Johnson, and P. J. Kumar, “Gastric lesion in dermatitis herpetiformis,” *Gut*, vol. 17, no. 3, pp. 185–188, 1976.

[11] R. Gillberg, W. Kastrup, H. Mobacken, R. Stockbrügger, and C. Ahren, “Gastric morphology and function in dermatitis herpetiformis and in coeliac disease,” *Scandinavian Journal of Gastroenterology*, vol. 20, no. 2, pp. 133–140, 1985.

[12] M. Primignani, D. Agape, G. Ronchi et al., “Gastroduodenal morphology and function in Italian patients with dermatitis herpetiformis,” *Scandinavian Journal of Gastroenterology*, vol. 25, no. 4, pp. 357–362, 1990.

[13] B. Annibale, R. Negrini, P. Caruana et al., “Two-thirds of atrophic body gastritis patients have evidence of *Helicobacter pylori* infection,” *Helicobacter*, vol. 6, no. 3, pp. 225–233, 2001.

[14] L. I. Veijola, A. M. Oksanen, P. I. Sipponen, and H. I. K. Rautelin, “Association of autoimmune type atrophic corpus gastritis with *Helicobacter pylori* infection,” *World Journal of Gastroenterology*, vol. 16, no. 1, pp. 83–88, 2010.

[15] P. Sipponen and A. B. Price, “The Sydney System for classification of gastritis 20 years ago,” *Journal of Gastroenterology and Hepatology*, vol. 26, supplement 1, pp. 31–34, 2011.

[16] J. B. van der Meer, “Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study,” *British Journal of Dermatology*, vol. 81, no. 7, pp. 493–503, 1969.

[17] T. T. Salmini, K. Hervonen, H. Kautiniemi, P. Collin, and T. Reunala, “Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland,” *British Journal of Dermatology*, vol. 165, no. 2, pp. 354–359, 2011.

[18] T. Storskrubb, P. Aro, J. Ronkainen et al., “A negative *Helicobacter pylori* serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current *H. pylori* infection: a report on histology and *H. pylori* detection in the general adult population,” *Scandinavian Journal of Gastroenterology*, vol. 40, no. 3, pp. 302–311, 2005.

[19] A. Telaranta-Keerie, R. Kara, L. Palohelm, M. Hrknen, and P. Sipponen, “Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints,” *Scandinavian Journal of Gastroenterology*, vol. 45, no. 9, pp. 1036–1041, 2010.

[20] J. E. Crabtree, S. O’Mahony, I. J. Wyatt et al., “*Helicobacter pylori* serology in patients with coeliac disease and dermatitis herpetiformis,” *Journal of Clinical Pathology*, vol. 45, no. 7, pp. 597–600, 1992.

[21] T. U. Kosunen, A. Aroma, P. Knekt et al., “*Helicobacter* antibodies in 1973 and 1994 in the adult population of Vammala, Finland,” *Epidemiology and Infection*, vol. 119, no. 1, pp. 29–34, 1997.

[22] G. Zettling, M. Weisel, J. Flores, R. Dudczak, and H. Vogelsang, “Dermatitis herpetiformis is associated with atrophic but not with goitrous variant of Hashimoto’s thyroiditis,” *European Journal of Clinical Investigation*, vol. 30, no. 1, pp. 53–57, 2000.

[23] S. Kärpätä, “Dermatitis herpetiformis,” *Clinics in Dermatology*, vol. 30, no. 1, pp. 56–59, 2012.

[24] J. Parsonnet, G. D. Friedman, D. P. Vandersteen et al., “*Helicobacter pylori* infection and the risk of gastric carcinoma,” *New England Journal of Medicine*, vol. 325, no. 16, pp. 1127–1131, 1991.

[25] T. U. Kosunen, E. Pukkala, S. Sarna et al., “Gastric cancers in Finnish patients after cure of *Helicobacter pylori* infection: a cohort study,” *International Journal of Cancer*, vol. 128, no. 2, pp. 433–439, 2011.

[26] H. Andersson, A. C. Bjorkman, and R. Gillberg, “Influence of the amount of dietary gluten on gastrointestinal morphology and function in dermatitis herpetiformis,” *Human Nutrition*, vol. 38, no. 4, pp. 279–285, 1984.

[27] W. Kastrup, H. Andersson, R. Gillberg, H. Mobacken, and R. Stockbrügger, “Influence of gluten-free diet on the gastric condition in dermatitis herpetiformis,” *Scandinavian Journal of Gastroenterology*, vol. 20, no. 1, pp. 39–45, 1985.

[28] B. Sigurgeirsson, B. A. Agnarsson, and B. Lindehof, “Risk of lymphoma in patients with dermatitis herpetiformis,” *British Medical Journal*, vol. 308, no. 6920, pp. 13–15, 1994.

[29] H. M. Lewis, T. L. Renaula, J. J. Garioch et al., “Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis,” *British Journal of Dermatology*, vol. 135, no. 3, pp. 363–367, 1996.

[30] M. Viljamaa, K. Kaukinen, E. Pukkala, K. Hervonen, T. Reunala, and P. Collin, “Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study,” *Digestive and Liver Disease*, vol. 38, no. 6, pp. 374–380, 2006.